Mycosis Fungoides News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

MAVORIC Study Shows Survival Improved With Mogamulizumab in ... - Targeted Oncology



Targeted Oncology
 
MAVORIC Study Shows Survival Improved With Mogamulizumab in ... 
Targeted Oncology
Mogamulizumab improved progression-free survival in previously treated patients with cutaneous T-cell lymphoma by 4.6 months compared with vorinostat (Zolinza), according to findings from the phase III MAVORIC study.
Mogamulizumab superior to vorinostat for cutaneous T-cell lymphoma Healio

all 3 news articles » 


Seattle Genetics Highlights Updated Analyses from Phase 3 ALCANZA Clinical Trial of ADCETRIS - Business Wire (press release)



Seattle Genetics Highlights Updated Analyses from Phase 3 ALCANZA Clinical Trial of ADCETRIS 
Business Wire (press release)
The presentation highlighted longer-term durability data from the phase 3 ALCANZA clinical trial of single-agent ADCETRIS for the treatment of patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides ...

and more » 


Philly firefighters and cancer: Coincidence or job hazard? - Philly.com



Philly.com
 
Philly firefighters and cancer: Coincidence or job hazard? 
Philly.com
Patients with mycosis fungoides have a good prognosis with the proper care. But for now, cancer treatments leave Olsen exhausted. Firefighters ?really want to go to work,? Olsen said. ?It's a strange but true fact of a firehouse.? Robert Daniels, the ...

 


Immunomedics' Data Is Good News for Seattle Genetics, Too - Motley Fool



Immunomedics' Data Is Good News for Seattle Genetics, Too 
Motley Fool
Adcetris is also used to treat patients with systemic anaplastic large-cell lymphoma whose disease has progressed after one prior chemotherapy treatment, and in November, the FDA approved it for use in primary cutaneous anaplastic large cell lymphoma ...

and more » 


Brentuximab Vedotin Nears European Approval for CTCL - OncLive



OncLive
 
Brentuximab Vedotin Nears European Approval for CTCL 
OncLive
If approved in Europe, Adcetris would offer a novel treatment option for CD30-expressing CTCL patients.? The CHMP reviewed findings from the international, open-label, phase III ALCANZA trial which showed that brentuximab vedotin induced responses ...

 


Mycosis Fungoides Market Research Report 2017 - Insider Tradings



Insider Tradings
 
Mycosis Fungoides Market Research Report 2017 
Insider Tradings
Mycosis Fungoides-Mechanism of action Insights, 2017?, report provides comprehensive insights of the ongoing therapeutic research and development across Mycosis Fungoides. The report provides a complete understanding of the pipeline activities ...

and more » 


FDA Approves Adcetris for Most Common Subtypes of Cutaneous T-cell Lymphoma - Lymphoma News Today



Lymphoma News Today
 
FDA Approves Adcetris for Most Common Subtypes of Cutaneous T-cell Lymphoma 
Lymphoma News Today
The U.S. Food and Drug Administration (FDA) has approved Seattle Genetics' Adcetris (brentuximab vedotin) for the treatment of adults with the two most common subtypes of cutaneous T-cell lymphoma (CTCL) ? non-Hodgkin lymphoma that primarily affects ...
Seattle Genetics wins new OK for Adcetris BioPharma Dive
Seattle Genetics' Adcetris Gets FDA Nod for Label Expansion Nasdaq

all 3 news articles » 


Psoriasis patients have a heightened risk of malignant lymphoma - ModernMedicine



Psoriasis patients have a heightened risk of malignant lymphoma 
ModernMedicine
A large population-based study using a general practice research database in the UK found an 11 fold increase risk of cutaneous T-cell lymphoma in severe psoriasis1 and a Danish cohort study found a 15 fold increase risk of mycosis fungoides - the most ...

 


Form 6-K Trillium Therapeutics For: Nov 29 - StreetInsider.com



StreetInsider.com
 
Form 6-K Trillium Therapeutics For: Nov 29 
StreetInsider.com
A Phase 1 clinical trial (NCT02663518) evaluating intravenous dosing of SIRPaFc in patients with advanced cancer is ongoing, and a second Phase 1 trial evaluating direct intratumoral injections is underway in solid tumors and mycosis fungoides ...
Zacks' 7 Best Strong Buys for 2018 Zacks.com

all 19 news articles » 


US FDA approve Seattle Genetics' Adcetris for pcALCL and CD30-expressing mycosis fungoides - pharmabiz.com



US FDA approve Seattle Genetics' Adcetris for pcALCL and CD30-expressing mycosis fungoides 
pharmabiz.com
... mycosis fungoides, which are the most common types of cutaneous T-cell lymphoma, demonstrated superior efficacy with durable responses for long-term disease management when compared to standard of care treatment options methotrexate and bexarotene ...